Login / Signup

Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial.

Adam G StewartAndrew HendersonMichelle J BauerDavid L PatersonPatrick N A Harris
Published in: JAC-antimicrobial resistance (2021)
activity against ceftriaxone-resistant Enterobacterales bloodstream isolates and may be a suitable agent to be trialled for treatment of serious infections due to these organisms.
Keyphrases
  • klebsiella pneumoniae
  • escherichia coli
  • multidrug resistant
  • gram negative
  • clinical trial
  • randomized controlled trial
  • phase ii
  • staphylococcus aureus
  • cystic fibrosis
  • combination therapy
  • smoking cessation